IBDEI03L ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4322,0)
 ;;=280.9^^38^302^75
 ;;^UTILITY(U,$J,358.3,4322,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4322,1,4,0)
 ;;=4^280.9
 ;;^UTILITY(U,$J,358.3,4322,1,5,0)
 ;;=5^Iron Defic Anemia(Unspecified)
 ;;^UTILITY(U,$J,358.3,4322,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,4323,0)
 ;;=285.1^^38^302^73
 ;;^UTILITY(U,$J,358.3,4323,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4323,1,4,0)
 ;;=4^285.1
 ;;^UTILITY(U,$J,358.3,4323,1,5,0)
 ;;=5^Iron Defic Anemia Due To Acute Blood Loss
 ;;^UTILITY(U,$J,358.3,4323,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,4324,0)
 ;;=280.0^^38^302^74
 ;;^UTILITY(U,$J,358.3,4324,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4324,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,4324,1,5,0)
 ;;=5^Iron Defic Anemia Due To Chronic Blood Loss
 ;;^UTILITY(U,$J,358.3,4324,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,4325,0)
 ;;=281.9^^38^302^94
 ;;^UTILITY(U,$J,358.3,4325,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4325,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,4325,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,4325,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,4326,0)
 ;;=281.0^^38^302^111
 ;;^UTILITY(U,$J,358.3,4326,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4326,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,4326,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,4326,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,4327,0)
 ;;=282.60^^38^302^101
 ;;^UTILITY(U,$J,358.3,4327,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4327,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,4327,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,4327,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,4328,0)
 ;;=282.62^^38^302^102
 ;;^UTILITY(U,$J,358.3,4328,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4328,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,4328,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,4328,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,4329,0)
 ;;=281.1^^38^302^112
 ;;^UTILITY(U,$J,358.3,4329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4329,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,4329,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,4329,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,4330,0)
 ;;=286.7^^38^302^45
 ;;^UTILITY(U,$J,358.3,4330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4330,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,4330,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,4330,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,4331,0)
 ;;=289.9^^38^302^108
 ;;^UTILITY(U,$J,358.3,4331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4331,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,4331,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,4331,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,4332,0)
 ;;=451.9^^38^302^109
 ;;^UTILITY(U,$J,358.3,4332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4332,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,4332,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,4332,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,4333,0)
 ;;=446.6^^38^302^110
 ;;^UTILITY(U,$J,358.3,4333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4333,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,4333,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,4333,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,4334,0)
 ;;=286.4^^38^302^113
 ;;^UTILITY(U,$J,358.3,4334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4334,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,4334,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,4334,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,4335,0)
 ;;=204.00^^38^302^5
 ;;^UTILITY(U,$J,358.3,4335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4335,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,4335,1,5,0)
 ;;=5^All, W/O Remission
 ;;^UTILITY(U,$J,358.3,4335,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,4336,0)
 ;;=204.01^^38^302^4
 ;;^UTILITY(U,$J,358.3,4336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4336,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,4336,1,5,0)
 ;;=5^All, In Remission
 ;;^UTILITY(U,$J,358.3,4336,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,4337,0)
 ;;=204.10^^38^302^42
 ;;^UTILITY(U,$J,358.3,4337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4337,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,4337,1,5,0)
 ;;=5^Cll, W/O Remission
 ;;^UTILITY(U,$J,358.3,4337,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,4338,0)
 ;;=204.11^^38^302^41
 ;;^UTILITY(U,$J,358.3,4338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4338,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,4338,1,5,0)
 ;;=5^Cll, In Remission
 ;;^UTILITY(U,$J,358.3,4338,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,4339,0)
 ;;=201.90^^38^302^72
 ;;^UTILITY(U,$J,358.3,4339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4339,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,4339,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,4339,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,4340,0)
 ;;=785.6^^38^302^79
 ;;^UTILITY(U,$J,358.3,4340,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4340,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,4340,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,4340,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,4341,0)
 ;;=200.20^^38^302^80
 ;;^UTILITY(U,$J,358.3,4341,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4341,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,4341,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,4341,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,4342,0)
 ;;=202.00^^38^302^82
 ;;^UTILITY(U,$J,358.3,4342,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4342,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,4342,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,4342,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,4343,0)
 ;;=200.10^^38^302^81
 ;;^UTILITY(U,$J,358.3,4343,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4343,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,4343,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,4343,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,4344,0)
 ;;=273.3^^38^302^83
 ;;^UTILITY(U,$J,358.3,4344,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4344,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,4344,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,4344,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,4345,0)
 ;;=203.00^^38^302^92
 ;;^UTILITY(U,$J,358.3,4345,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4345,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,4345,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,4345,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,4346,0)
 ;;=203.01^^38^302^91
 ;;^UTILITY(U,$J,358.3,4346,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4346,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,4346,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,4346,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,4347,0)
 ;;=238.6^^38^302^95
 ;;^UTILITY(U,$J,358.3,4347,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4347,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,4347,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,4347,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,4348,0)
 ;;=205.00^^38^302^7
 ;;^UTILITY(U,$J,358.3,4348,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4348,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,4348,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,4348,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,4349,0)
 ;;=205.01^^38^302^6
 ;;^UTILITY(U,$J,358.3,4349,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4349,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,4349,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,4349,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,4350,0)
 ;;=205.10^^38^302^44
 ;;^UTILITY(U,$J,358.3,4350,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4350,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,4350,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,4350,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,4351,0)
 ;;=205.11^^38^302^43
 ;;^UTILITY(U,$J,358.3,4351,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4351,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,4351,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,4351,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,4352,0)
 ;;=289.0^^38^302^46
 ;;^UTILITY(U,$J,358.3,4352,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4352,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,4352,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,4352,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,4353,0)
 ;;=238.4^^38^302^96
 ;;^UTILITY(U,$J,358.3,4353,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4353,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,4353,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,4353,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,4354,0)
 ;;=V58.61^^38^302^114
 ;;^UTILITY(U,$J,358.3,4354,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4354,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,4354,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,4354,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,4355,0)
 ;;=282.49^^38^302^106
 ;;^UTILITY(U,$J,358.3,4355,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4355,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,4355,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,4355,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,4356,0)
 ;;=289.89^^38^302^14
 ;;^UTILITY(U,$J,358.3,4356,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4356,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,4356,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,4356,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,4357,0)
 ;;=238.79^^38^302^77
 ;;^UTILITY(U,$J,358.3,4357,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4357,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,4357,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,4357,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,4358,0)
 ;;=287.30^^38^302^97
 ;;^UTILITY(U,$J,358.3,4358,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4358,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,4358,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,4358,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,4359,0)
 ;;=288.09^^38^302^3
 ;;^UTILITY(U,$J,358.3,4359,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4359,1,4,0)
 ;;=4^288.09
